CLNN vs. RMTI, BOLT, RVPH, IMRX, BLRX, AADI, NBRV, RPHM, NXTC, and EQ
Should you be buying Clene stock or one of its competitors? The main competitors of Clene include Rockwell Medical (RMTI), Bolt Biotherapeutics (BOLT), Reviva Pharmaceuticals (RVPH), Immuneering (IMRX), BioLineRx (BLRX), Aadi Bioscience (AADI), Nabriva Therapeutics (NBRV), Reneo Pharmaceuticals (RPHM), NextCure (NXTC), and Equillium (EQ). These companies are all part of the "pharmaceutical preparations" industry.
Clene (NASDAQ:CLNN) and Rockwell Medical (NASDAQ:RMTI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, community ranking, dividends, valuation and earnings.
In the previous week, Clene had 6 more articles in the media than Rockwell Medical. MarketBeat recorded 20 mentions for Clene and 14 mentions for Rockwell Medical. Clene's average media sentiment score of 0.33 beat Rockwell Medical's score of 0.32 indicating that Clene is being referred to more favorably in the media.
Rockwell Medical received 244 more outperform votes than Clene when rated by MarketBeat users. However, 75.32% of users gave Clene an outperform vote while only 57.41% of users gave Rockwell Medical an outperform vote.
Rockwell Medical has higher revenue and earnings than Clene. Rockwell Medical is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.
Clene has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500. Comparatively, Rockwell Medical has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500.
Rockwell Medical has a net margin of -10.09% compared to Clene's net margin of -7,873.23%. Rockwell Medical's return on equity of -39.17% beat Clene's return on equity.
Clene presently has a consensus price target of $6.50, suggesting a potential upside of 1,545.99%. Rockwell Medical has a consensus price target of $7.00, suggesting a potential upside of 299.50%. Given Clene's higher possible upside, equities analysts plainly believe Clene is more favorable than Rockwell Medical.
23.3% of Clene shares are held by institutional investors. Comparatively, 23.3% of Rockwell Medical shares are held by institutional investors. 25.1% of Clene shares are held by insiders. Comparatively, 1.9% of Rockwell Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Rockwell Medical beats Clene on 9 of the 17 factors compared between the two stocks.
Get Clene News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLNN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
